Thanks for signing up for DividendStocks.com! It's the daily newsletter built for dividend and income investors. Before we can begin sending your daily updates, there’s one quick step left. Please confirm your subscription using the link below so our emails reach your inbox. Click Here to Confirm Your Subscription to DividendStocks.com Here’s a small glimpse of what you’ll get access to: Dividend Stock Ideas — Each newsletter features dividend stocks with high yields, sustainable payouts, and strong growth potential. Ex-Dividend Stocks — Want to capture upcoming dividend payouts? Find out which stocks are going ex-dividend this week. Market News and Events — Stay in the loop on the latest developments impacting popular dividend names like AT&T, Exxon Mobil, IBM, Procter & Gamble, and Verizon. Bonus: As a thank-you for confirming, you’ll also receive a free PDF copy of Automatic Income, our popular guide to building wealth through dividend investing. Let’s get your dividend journey started! Discover Top Income-Generating Stocks Here See you in your inbox soon,
The DividendStocks.com Team P.S. Don’t miss out click here to verify your subscription and secure your daily dividend insights and your free investing guide!
Special Report A Fresh IPO That Long-Term Investors Shouldn't IgnoreSubmitted by Jordan Chussler. First Published: 1/14/2026. 
Quick Look - While IPOs are often labeled as high-risk startups, some are worthy of more conservative investors’ attention.
- Aktis Oncology’s IPO—the first biotech IPO of 2026—resulted in a $318 million raise, with the biotech firm receiving $100 million in backing from Big Pharma giant Eli Lilly.
- The company, which now has a market cap of $3.34 billion, develops radiopharmaceuticals and is positioned for long-term success after being listed on the Nasdaq.
For speculative investors, the start of each year is always a good time to revisit an initial public offering (IPO) calendar. Almost every week, companies go public, and a handful of them offer considerable short-term upside potential. Of course, they also carry substantial downside risk. But even conservative investors who err on the side of caution shouldn't dismiss every newly public company—some recent IPOs may justify a place in buy-and-hold portfolios. A freight train pulling 50 railcars can be worth $2 million in economic value. That's the idea behind a new trading concept called the Money Train Method. Imagine bumping your win rate from 50 percent up to 60, 75, or even 80 percent while increasing each trade's profit potential to an average gain of 20 to 30 percent, with triple-digit runners possible. The strategy also builds in downside protection with a reward-to-risk ratio of 1.2 to 1. See how the Money Train Method works. For one biotechnology firm in the healthcare sector that just went public, that may be the case. Last Year's IPO Success Stories Last year offers a good example of why newly public companies shouldn't be written off by investors with lower risk tolerances. AI cloud computing provider CoreWeave (NASDAQ: CRWV), which went public in March 2025, is up nearly 123% since then. Short-term speculators may have benefited from its roughly 359% gain within the first 30 days on the Nasdaq, but longer-term holders have also enjoyed strong returns. Others, such as Medline (NASDAQ: MDLN), dispel the notion that all IPOs are risky startups. The medical products and services provider, which debuted publicly in December 2025, was founded in 1966 and already has a market cap north of $55 billion. Similarly, Smithfield Foods (NASDAQ: SFD)—known for its ubiquitous packages of bacon—waited 89 years before going public. Since listing in January 2025, the stock is up nearly 5% and has rewarded shareholders with a dividend that currently yields 4.44% (about $1 per share annually), making it an immediate consideration for income investors. After its IPO and with shares hitting the market on Jan. 9, Aktis Oncology (NASDAQ: AKTS), a developer of radiopharmaceuticals, is hoping for a similar outcome in 2026 and beyond. Why Are Radiopharmaceuticals Important? Aktis Oncology specializes in radiopharmaceuticals—a subset of nuclear medicine that uses radioactive drugs for both diagnostics and treatment of conditions such as cancer, heart disease and neurological disorders. Radiopharmaceuticals combine radioactive isotopes with a targeting module that seeks out particular cells (for example, cancer cells) to deliver localized doses of radiation. This targeted approach can minimize damage to healthy tissue compared with some conventional radiation treatments. According to industry consultancy Grand View Research, the global nuclear medicine market, estimated at nearly $18 billion in 2024, is forecast to reach almost $35 billion by 2030—a compound annual growth rate of about 10.16%. Grand View Research also notes that the North American segment accounts for nearly 43% of the global nuclear medicine market, with the United States as the predominant player—an important point for Boston-based Aktis Oncology. Aktis Oncology's Clinical-Stage Profile Wall Street expects biotech IPOs to rebound in 2026 after funding cuts in 2025 slowed healthcare listings. Aktis Oncology, which debuted on the Nasdaq on Jan. 9, was the first biotech IPO of 2026 and one of the largest biotech raises in recent memory. The offering brought in $318 million and the firm now carries a market capitalization of roughly $3.34 billion. According to the company's prospectus, the executive team includes experts in drug development, approval and commercialization, with members having participated in bringing 14 currently FDA-approved products to market. Aktis develops targeted alpha radiopharmaceuticals—a class of precision cancer drugs that use proprietary technology to target solid tumors while sparing healthy tissue. Aktis Oncology's Eli Lilly Connection Notably, Aktis is clinical-stage and pre-revenue, but that did not deter Eli Lilly (NYSE: LLY) from anchoring its IPO. According to Reuters, Eli Lilly purchased $100 million worth of AKTS shares in the offering. That investment builds on a 2024 partnership between the companies to develop tumor-targeting radiopharmaceuticals, under which Aktis received $60 million in cash and an equity investment from Lilly, with potential milestone payments that could exceed $1 billion. The significance of Lilly's backing is substantial. At about $1.01 trillion, Eli Lilly is the largest Big Pharma company by market cap; its net income jumped nearly 109% year-over-year from 2023 to 2024. That momentum is likely to be further highlighted when Lilly reports Q4 and full-year 2025 financials on Feb. 5. Between its equity stake and the recent $100 million in AKTS shares purchased at the IPO, the maker of Zepbound now has a sizable financial interest in the biotech startup's success.
| 
